# FIDUS INVESTMENT Corp: overview FDUS · Nasdaq · CIK 1513363 · [Other](/sectors/other.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fdus.md) · [Financials](/companies/fdus/financials.md) · [Filings](/companies/fdus/filings.md) · [Insiders](/companies/fdus/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.64](/filings/0001193125-26-076572.md) | [0.55](/filings/0001193125-26-076572.md) | [0.53](/filings/0001193125-26-211915.md) | [0.53](/filings/0001193125-26-337982.md) | [0.49](/filings/0001193125-26-076572.md) | [0.53](/filings/0001193125-26-076572.md) | [0.65](/filings/0001193125-26-211915.md) | [0.49](/filings/0001193125-26-337982.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [1.03](/filings/0000950170-24-023065.md) | [1.90](/filings/0000950170-25-034612.md) | [2.47](/filings/0001193125-26-076572.md) | [2.29](/filings/0001193125-26-076572.md) | [2.08](/filings/0001193125-26-076572.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fdus/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VAN ECK ASSOCIATES CORP](/funds/869178.md) | 2026-06-30 | $17.7m | 929,242 | | Added +216,180 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $15.8m | 829,588 | | Added +25,196 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $9.5m | 499,624 | | Added +76,732 | | [Baird Financial Group, Inc.](/funds/1648711.md) | 2026-06-30 | $7.9m | 416,390 | | Added +9,964 | | [Muzinich & Co., Inc.](/funds/1618824.md) | 2026-06-30 | $7.0m | 368,298 | | Added +19,987 | | [Legal & General Group Plc](/funds/764068.md) | 2026-06-30 | $5.9m | 310,317 | | Added +25,857 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $5.8m | 302,643 | | Added +8,476 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $4.4m | 230,205 | | Added +126,804 | | [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $4.4m | 230,108 | | Added +16,723 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $4.3m | 224,978 | | Added +72,699 | ## Recent filings [All 525 filings](/companies/fdus/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:09 ET | [10-Q](/filings/0001193125-26-337982.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337982 | | 2026-08-06 | 16:08 ET | [8-K](/filings/0001193125-26-337972.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-337972 | | 2026-06-24 | 16:56 ET | [8-K](/filings/0001193125-26-281224.md) | 5.07 Shareholder vote results | 0001193125-26-281224 | | 2026-06-11 | 16:06 ET | [8-K](/filings/0001193125-26-267516.md) | 8.01 Other events | 0001193125-26-267516 | | 2026-05-29 | 16:08 ET | [8-K](/filings/0001193125-26-248266.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-248266 | | 2026-05-07 | 16:13 ET | [10-Q](/filings/0001193125-26-211915.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211915 | | 2026-05-07 | 16:11 ET | [8-K](/filings/0001193125-26-211909.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-211909 | | 2026-03-20 | 08:38 ET | [DEF 14A](/filings/0001193125-26-116813.md) | Proxy statement, period 2026-03-19 | 0001193125-26-116813 | | 2026-03-02 | 16:04 ET | [8-K](/filings/0001193125-26-085360.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-085360 | | 2026-02-26 | 16:09 ET | [10-K](/filings/0001193125-26-076572.md) | Annual report, period 2025-12-31 | 0001193125-26-076572 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076572.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1513363 - Tickers: FDUS - Exchange: Nasdaq - SIC code: not reported - State of incorporation: MD - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:31 ET. No prices; not investment advice.